{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:09Z","timestamp":1792265049637,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11060-025-05026-9","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:14:20Z","timestamp":1743887660000},"page":"619-625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases"],"prefix":"10.1007","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9046-6581","authenticated-orcid":false,"given":"Allen Ye","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9484-2601","authenticated-orcid":false,"given":"Kenneth","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7276-7962","authenticated-orcid":false,"given":"Jeff","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-3826","authenticated-orcid":false,"given":"Joshua","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-9264","authenticated-orcid":false,"given":"Janice","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-9120","authenticated-orcid":false,"given":"Erik P.","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5963","authenticated-orcid":false,"given":"Eric Karl","family":"Oermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-7344","authenticated-orcid":false,"given":"Douglas","family":"Kondziolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"5026_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","volume":"135","author":"JK Patel","year":"1978","unstructured":"Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135:807\u2013810","journal-title":"Am J Surg"},{"key":"5026_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A et al (2019) Long-Term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37:52\u201360","journal-title":"J Clin Oncol"},{"key":"5026_CR3","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722\u2013730","journal-title":"N Engl J Med"},{"key":"5026_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687\u20131696","journal-title":"Cancer"},{"key":"5026_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11060-020-03427-6","volume":"151","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, McGee HM, Sheehan JP, Trifiletti DM (2021) Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases. J Neurooncol 151:75\u201384","journal-title":"J Neurooncol"},{"key":"5026_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40425-017-0282-x","volume":"5","author":"ES Anderson","year":"2017","unstructured":"Anderson ES, Postow MA, Wolchok JD et al (2017) Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer 5:76","journal-title":"J Immunother Cancer"},{"key":"5026_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-018-2880-y","volume":"139","author":"K Diao","year":"2018","unstructured":"Diao K, Bian SX, Routman DM et al (2018) Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. J Neurooncol 139:421\u2013429","journal-title":"J Neurooncol"},{"key":"5026_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/COC.0000000000000199","volume":"40","author":"KR Patel","year":"2017","unstructured":"Patel KR, Shoukat S, Oliver DE et al (2017) Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol 40:444\u2013450","journal-title":"Am J Clin Oncol"},{"key":"5026_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/CAD.0000000000000497","volume":"28","author":"O Kaidar-Person","year":"2017","unstructured":"Kaidar-Person O, Zagar TM, Deal A et al (2017) The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Anticancer Drugs 28:669\u2013675","journal-title":"Anticancer Drugs"},{"key":"5026_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/pcmr.12775","volume":"32","author":"I Pires da Silva","year":"2019","unstructured":"Pires da Silva I, Glitza IC, Haydu LE et al (2019) Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res 32:553\u2013563","journal-title":"Pigment Cell Melanoma Res"},{"key":"5026_CR11","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1002\/cncr.32454","volume":"125","author":"G Schvartsman","year":"2019","unstructured":"Schvartsman G, Ma J, Bassett RL Jr et al (2019) Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer 125:4193\u20134202","journal-title":"Cancer"},{"key":"5026_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3171\/2016.9.JNS161585","volume":"127","author":"O Cohen-Inbar","year":"2017","unstructured":"Cohen-Inbar O, Shih H-H, Xu Z et al (2017) The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. J Neurosurg 127:1007\u20131014","journal-title":"J Neurosurg"},{"key":"5026_CR13","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","volume":"116","author":"EJ Lehrer","year":"2023","unstructured":"Lehrer EJ, Kowalchuk RO, Gurewitz J et al (2023) Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases. Int J Radiat Oncol Biol Phys 116:858\u2013868","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5026_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-018-03020-y","volume":"141","author":"VM Lu","year":"2019","unstructured":"Lu VM, Goyal A, Rovin RA et al (2019) Concurrent versus non-concurrent immune checkpoint Inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. J Neurooncol 141:1\u201312","journal-title":"J Neurooncol"},{"key":"5026_CR15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1227\/neu.0000000000002542","volume":"93","author":"Z Schnurman","year":"2023","unstructured":"Schnurman Z, Mashiach E, Link KE et al (2023) Causes of death in patients with brain metastases. Neurosurgery 93:986\u2013993","journal-title":"Neurosurgery"},{"key":"5026_CR16","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1038\/s41467-024-52414-2","volume":"15","author":"KE Link","year":"2024","unstructured":"Link KE, Schnurman Z, Liu C et al (2024) Longitudinal deep neural networks for assessing metastatic brain cancer on a large open benchmark. Nat Commun 15:8170","journal-title":"Nat Commun"},{"key":"5026_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546","journal-title":"N Engl J Med"},{"key":"5026_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"5026_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"5026_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1080\/02688697.2021.2022098","volume":"37","author":"S Badrigilan","year":"2023","unstructured":"Badrigilan S, Meola A, Chang SD et al (2023) Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. Br J Neurosurg 37:1533\u20131543","journal-title":"Br J Neurosurg"},{"key":"5026_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-023-04312-8","volume":"163","author":"JA Tracz","year":"2023","unstructured":"Tracz JA, Donnelly BM, Ngu S et al (2023) The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. J Neurooncol 163:1\u201314","journal-title":"J Neurooncol"},{"key":"5026_CR22","first-page":"100573","volume":"39","author":"R Bodensohn","year":"2023","unstructured":"Bodensohn R, Werner S, Reis J et al (2023) Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. Clin Transl Radiat Oncol 39:100573","journal-title":"Clin Transl Radiat Oncol"},{"key":"5026_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00735-6","author":"GV Long","year":"2025","unstructured":"Long GV, Atkinson V, Lo SN et al (2025) Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(24)00735-6","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05026-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T10:47:25Z","timestamp":1750070845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["5026"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05026-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As previously discussed, this study was conducted under an institutional review board approved protocol with a waiver of authorization and informed consent given minimal risk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}